Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT

VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. No dose limiting toxicities were observed in any of the cancer patients and two out of three patients with ovarian cancer responded positively and exhibited stable disease.

Chemokine Therapeutics will now proceed with the remaining portion of the clinical trial in which up to twenty additional patients will be treated at 5mg/kg/day. The Company expects to enroll the remainder of the patients and complete the current trial by the end of Q3 2007. The Company has also accelerated its efforts to initiate a large Phase II program in the U.S. by the end of 2007. Accordingly, a pre-IND meeting has been scheduled with the FDA to discuss the Company's future clinical trial program.

"We are very pleased that no dose-limiting toxicities were observed in the first part of the trial and encouraged by the positive outcome in the small group of ovarian cancer patients," said Dr. Hassan Salari, Chemokine Therapeutics President and CEO. "It is quite remarkable to see clinical evidence of efficacy considering these patients have exhausted every therapeutic avenue. We are now looking to rapidly expand the number of patients in Phase II clinical trials of CTCE-9908 to examine the potential broader applicability of this novel oncology drug in the treatment of cancer patients."

The primary purpose of this study is dose-selection and evaluation of safety and tolerability of CTCE-9908. CTCE-9908 is administered via a 30-minute infusion on weekdays over a treatment p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/15/2014)... MEETING, Pa. , Dec. 15, 2014 /PRNewswire/ ... announced today it has been added to the ... NASDAQ Biotechnology Index will become effective upon market ... NASDAQ Biotechnology Index is designed to track the ... are classified as either biotechnology or pharmaceutical according ...
(Date:12/15/2014)... -- Colorado and Washington State are not ... Oregon , Alaska , ... the November 2014 elections. Photo - ... The benefits of legalizing cannabis are manifold. There ... increased tax revenue for state and local governments, in addition ...
(Date:12/15/2014)... , Dec. 15, 2014 As medical ... (Structured Product Labeling) markup language standard, content teams have ... and skills to work with the standard. Starting January ... of three webinars on the benefits and the critical ... webinars will be facilitated by Howard Shatz , ...
Breaking Medicine Technology:Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3
... YORK, April 6, 2011 KellBenx, a biotechnology ... diagnosis (NIPD) of genetic and inherited disorders, announced ... with AdnaGen, a wholly-owned subsidiary of Alere, Inc., ... will have exclusive worldwide rights to commercialize the ...
... 6, 2011 /PRNewswire/ -- Royal Philips ... United States availability of the Ingenia MRI system, ... solution. Previously available in Europe, Canada and Japan, ... U.S. Food and Drug Administration. Driven by Philips ...
Cached Medicine Technology:KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies 2Philips to Take Orders for the Ingenia MRI System in the United States 2Philips to Take Orders for the Ingenia MRI System in the United States 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , VIRGINIA BEACH, Va., Jan. 11, 2010 Amerigroup ... report its earnings for the fourth quarter and the fiscal year ... Friday, February 19, 2010. At 8:30 a.m. Eastern Time on ... webcast to discuss earnings and other information. , To listen to ...
... , KNOXVILLE, Tenn., Jan. 11 TeamHealth ... that the underwriters of its recent initial public offering of ... an additional 1,995,000 shares of common stock from the Company ... intends to use the additional net proceeds of approximately $22.5 ...
... Jan. 11 The California Dental Association (CDA) ... charitable Dental Student Loan Repayment Grant Program. Two California ... each receive a maximum of $105,000 to help offset ... commitment to work in an underserved community. , ...
... to be part of the ,culture, at some centers, one ... Americans in nursing homes still get powerful antipsychotic medications, despite ... practice, two new studies show. , The practice can control ... U.S. Food and Drug Administration instituted a "black box" warning ...
... ... Corpus Christi and Austin, Texas areas. , ... San Antonio, TX (PRWEB) January 11, 2010 -- Physicians Health ... choices and benefits than original Medicare -- is pleased to announce it is partnering ...
... , SC AG McMaster to ... , WASHINGTON, Jan. 11 South Carolina Attorney ... general into the constitutionality of the health care reform bill ... press conference at 2:00 p.m. on Wednesday, January 13th, ...
Cached Medicine News:Health News:Amerigroup Corporation to Discuss Fourth Quarter and 2009 Year-End Earnings on February 19 2Health News:TeamHealth Announces Exercise of Over-Allotment Option for Previously Announced Initial Public Offering 2Health News:TeamHealth Announces Exercise of Over-Allotment Option for Previously Announced Initial Public Offering 3Health News:TeamHealth Announces Exercise of Over-Allotment Option for Previously Announced Initial Public Offering 4Health News:California Dental Association Foundation Awards More Than $200,000 in Community Service Grants 2Health News:Antipsychotics Still Widely Used in U.S. Nursing Homes 2Health News:Antipsychotics Still Widely Used in U.S. Nursing Homes 3Health News:Top-Rated Medicare Plan Now Offers Silver Life Fitness Program Free to its Members 2Health News:Top-Rated Medicare Plan Now Offers Silver Life Fitness Program Free to its Members 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: